Skip to content
Gold Mining News – Lifestyle
Home
Sample Page
Author:
Arvinas Inc.
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 4, 2026
Arvinas to Present at Jefferies Global Healthcare Conference
May 29, 2026
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
May 5, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
May 3, 2026
1
2
Next Page
→